During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase I for Essential Thrombocythemia. According to GlobalData, Phase I drugs for Essential Thrombocythemia does not ...

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase II drugs for Myelodysplastic Syndrome have a ...

The treatment has been around for over a century but insulin has still become the centre of the ongoing discussion over pricing of pharmaceutical products. Ben Hargreaves looks at why insulin’s ...

After treating a tumor with chemotherapy and radiotherapy, cells known as senescent cells can appear. These are cells that do not divide, are involved in the aging process, and are resistant to cell ...

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech's shares skywards.

Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199] Technology appraisal guidance TBC Vepdegestrant for treating ...

The findings were remarkable. When the mice were treated with both partial normoxic recovery (mimicking proper CPAP use) and a senolytic drug called Navitoclax (NAV), they showed significant ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

After treating a tumour with chemotherapy and radiotherapy, cells known as senescent cells can appear. These are cells that do not divide, are involved in the ageing process and are resistant to cell ...

Macromolecular Engineering Laboratory, Institute of Energy and Process Engineering, Department of Mechanical and Process Engineering, ETH Zurich, 8092 Zurich, Switzerland Institute for Mechanical ...